



DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics

May 13, 2016

SALUGGIA, Italy, May 13, 2016 /PRNewswire/ -- DiaSorin S.p.A. (FTSE Italy: DIA) today announced the completion of the transaction to acquire the Focus Diagnostics' immunodiagnostic and molecular diagnostic products business ("**Focus**") from Quest Diagnostics (NYSE: DGX), initiated with a binding purchase agreement signed on March 29, 2016.



DiaSorin paid to Quest Diagnostics \$300 million in cash for all the tangible and intangible assets of Focus used by the latter to develop, manufacture and distribute its molecular diagnostic products and its traditional immunoassay ELISA products, including among other relevant intellectual property, contracts and customer list.

Focus' product lines include the Simplexa™ molecular product line, HerpeSelect® HSV serology, and a line of DxSelect™ IFA and ELISA assays that will continue to be manufactured by the relevant facility in Cypress, California, USA.

The transaction does not include Quest Diagnostics' diagnostic information services laboratories currently operating under the Focus Diagnostics brand.

The transaction's main terms and conditions are those already made available by both parties to the public on March 30, 2016.

About DiaSorin:

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD "diagnostics specialist".

About Quest Diagnostics:

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 44,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com

For additional information, please contact:

Diasorin:

Riccardo Fava

Investor Relations & Corporate Communication Senior Director

Tel. +39.0161.487.988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel. +39.0161.487.567

ines.diterlizzi@diasorin.it

Quest Diagnostics:

Shawn Bevec (Investors) 973-520-2900 (US)

Wendy Bost (Media) 973-520-2800 (US)

Logo - <http://photos.prnewswire.com/prnh/20150422/200883LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/diasorin-spa-completes-acquisition-of-the-focus-diagnostics-molecular-and-immunoassay-product-business-from-quest-diagnostics-300268614.html>

SOURCE Quest Diagnostics